JKA97, a novel benzylidene analog of harmine, exerts anti-cancer effects by inducing G1 arrest, apoptosis, and p53-independent up-regulation of p21

PLoS ONE

Volumn 7, Issue 4, 2012, Pages

  Yang, Xinyi ^a   Wang, Wei ^a   Qin, Jiang Jiang ^a   Wang, Ming Hai ^a   Sharma, Horrick ^b   Buolamwini, John K ^b   Wang, Hui ^c   Zhang, Ruiwen ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c Shanghai Jiao Tong University Affiliated Sixth People s Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN D1; CYCLIN E; METHOXY 1 STYRYL 9H PYRIDO[3,4 B]INDOLE; PROTEIN P21; PROTEIN P53; UNCLASSIFIED DRUG; 1 STYRYL 9H PYRIDO(3,4 B)INDOLE; 1-STYRYL-9H-PYRIDO(3,4-B)INDOLE; BENZYLIDENE DERIVATIVE; CARBOLINE DERIVATIVE; CYCLIN DEPENDENT KINASE INHIBITOR 1A; HARMINE; STYRENE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MITOSIS INHIBITION; MOUSE; NONHUMAN; PROTEIN DEGRADATION; PROTEIN STABILITY; TUMOR XENOGRAFT; BREAST TUMOR; CHEMISTRY; DOSE RESPONSE; DRUG EFFECT; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION REGULATION; METABOLISM; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZYLIDENE COMPOUNDS; BREAST NEOPLASMS; CARBOLINES; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; G1 PHASE CELL CYCLE CHECKPOINTS; GENE EXPRESSION REGULATION; HARMINE; HUMANS; STYRENES;

EID: 84860436144     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0034303     Document Type: Article

References (25)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
2. Nathanson KL, Domchek SM, (2011) Therapeutic approaches for women predisposed to breast cancer. Annu Rev Med 62: 295-306.
3. Oakman C, Santarpia L, Di Leo A, (2010) Breast cancer assessment tools and optimizing adjuvant therapy. Nat Rev Clin Oncol 7: 725-732.
4. Eskelinen M, Hippelainen M, Kettunen J, Salmela E, Penttila I, et al. (1994) Clinical value of serum tumour markers TPA, TPS, TAG 12, CA 15-3 and MCA in breast cancer diagnosis; results from a prospective study. Anticancer Res 14: 699-703.
5. Koehn FE, Carter GT, (2005) The evolving role of natural products in drug discovery. Nat Rev Drug Discov 4: 206-220.
6. Mishra BB, Tiwari VK, (2011) Natural products: An evolving role in future drug discovery. Eur J Med Chem 46: 4769-4807.
7. Song Y, Kesuma D, Wang J, Deng Y, Duan J, et al. (2004) Specific inhibition of cyclin-dependent kinases and cell proliferation by harmine. Biochem Biophys Res Commun 317: 128-132.
8. Ishida J, Wang HK, Bastow KF, Hu CQ, Lee KH, (1999) Antitumor agents 201. Cytotoxicity of harmine and beta-carboline analogs. Bioorg Med Chem Lett 9: 3319-3324.
9. Ma Y, Wink M, (2010) The beta-carboline alkaloid harmine inhibits BCRP and can reverse resistance to the anticancer drugs mitoxantrone and camptothecin in breast cancer cells. Phytother Res 24: 146-149.
10. Luo W, Liu J, Li J, Zhang D, Liu M, et al. (2008) Anti-cancer effects of JKA97 are associated with its induction of cell apoptosis via a Bax-dependent and p53-independent pathway. J Biol Chem 283: 8624-8633.
11. Janssen A, Medema RH, (2011) Mitosis as an anti-cancer target. Oncogene 30: 2799-2809.
12. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ, (1993) The p21 cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinase. Cell 75: 805-816.
13. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, et al. (1993) p21 is a universal inhibitor of cyclin kinases. Nature 366: 701-704.
14. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, et al. (1993) WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817-825.
15. Zhang Z, Wang H, Li M, Agrawal S, Chen X, et al. (2004) MDM2 is a negative regulator of p21 WAF1/CIP1, independent of p53. J Biol Chem 279: 16000-16006.
16. LaBaer J, Garrett MD, Stevenson LF, Slingerland JM, Sandhu C, et al. (1997) New functional activities for the p21 family of CDK inhibitors. Genes Dev 11: 847-862.
17. Cheng M, Olivier P, Diehl JA, Fero M, Roussel MF, et al. (1999) The p21(Cip1) and p27(Kip1) CDK "inhibitors" are essential activators of cyclin D-dependent kinases in murine fibroblasts. EMBO J 18: 1571-1583.
18. Gartel A, Tyner A, (2002) The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol Cancer Ther 1: 639-649.
19. Kang KH, Kim WH, Choi KH, (1999) p21 promotes ceramide induced apoptosis and antagonizes the antideath effect of Bcl-2 in human hepatocarcinoma cells. Exp Cell Res 253: 403-412.
20. Wang W, Rayburn ER, Velu SE, Chen D, Nadkarni DH, et al. (2010) A novel synthetic iminoquinone, BA-TPQ, as an anti-breast cancer agent: in vitro and in vivo activity and mechanisms of action. Breast Cancer Res Treat 123: 321-331.
21. Wang W, Rayburn ER, Velu SE, Nadkarni DH, Murugesan S, et al. (2009) In vitro and in vivo anticancer activity of novel synthetic makaluvamine analogues. Clin Cancer Res 15: 3511-3518.
22. Wang W, Zhao YQ, Rayburn ER, Hill DL, Wang H, et al. (2007) In vitro anti-cancer activity and structure-activity relationships of natural products isolated from fruits of Panax ginseng. Cancer Chemother Pharmacol 59: 589-601.
23. Wang W, Wang H, Rayburn ER, Zhao YQ, Hill DL, et al. (2008) 20(S)-25-methoxyl-dammarane-3beta, 12beta, 20-triol, a novel natural product for prostate cancer therapy: activity in vitro and in vivo and mechanisms of action. Br J Cancer 26: 792-802.
24. Wang W, Rayburn ER, Hang J, Zhao YQ, Wang H, et al. (2009) Anti-lung cancer effects of novel ginsenoside 25-OCH(3)-PPD. Lung Cancer 65: 306-311.
25. Wang W, Rayburn ER, Zhao YQ, Wang H, Zhang RW, (2009) Novel ginsenosides 25-OH-PPD and 25-OCH3-PPD as experimental therapy for pancreatic cancer: anticancer activity and mechanisms of action. Cancer Lett 18: 241-248.